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Abstract 
Background: Sepsis is a major health issue in preterm infants. Biomarkers are used to diagnose and monitor patients 
with sepsis, but C-reactive protein (CRP) is proven not predictive at onset of late onset neonatal sepsis (LONS) diag-
nosis. The aim of this study was to evaluate the association of interleukin-6(IL-6), procalcitonin (PCT) and CRP with 
subsequent sepsis severity and mortality in preterm infants suspected of late onset neonatal sepsis.
Methods: The study was conducted at the Erasmus University Medical Center–Sophia Children’s Hospital Rotterdam. 
Patient data from January 2018 until October 2019 were reviewed for all preterm neonates born with a gestational 
age below 32 weeks with signs and symptoms suggestive of systemic infection, in whom blood was taken for blood 
culture and for inflammatory biomarkers determinations. Plasma IL-6 and PCT were assessed next to CRP at the 
moment of suspicion. We assessed the association with 7-day mortality and sepsis severity (neonatal sequential organ 
failure assessment (nSOFA) score, need for inotropic support, invasive ventilation and thrombocytopenia).
Results: A total of 480 suspected late onset neonatal sepsis episodes in 208 preterm neonates (gestational 
age < 32 weeks) were retrospectively analyzed, of which 143 episodes were classified as sepsis (29.8%), with 56 (11.7%) 
cases of culture negative, 63 (13.1%) cases of gram-positive and 24(5.0%) cases of gram-negative sepsis. A total of 24 
(5.0%) sepsis episodes resulted in death within 7 days after suspicion of LONS. Both IL-6 (adjusted hazard ratio (aHR): 
2.28; 95% CI 1.64–3.16; p < 0.001) and PCT (aHR: 2.91; 95% CI 1.70–5.00; p < 0.001) levels were associated with 7-day 
mortality; however, CRP levels were not significantly correlated with 7-day mortality (aHR: 1.16; 95% CI (0.68–2.00; 
p = 0.56). Log IL-6, log PCT and log CRP levels were all significantly correlated with the need for inotropic support.
Conclusions: Our findings show that serum IL-6 and PCT levels at moment of suspected late onset neonatal sepsis 
offer valuable information about sepsis severity and mortality risk in infants born below 32 weeks of gestation. The 
discriminative value was superior to that of CRP. Determining these biomarkers in suspected sepsis may help identify 
patients with imminent severe sepsis, who may require more intensive monitoring and therapy.
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Introduction
Neonatal sepsis is a major health issue, particularly 
in the preterm neonatal population, where low birth 
weight, immature immune system and other compro-
mising factors make it a primary cause of morbidity and 
death [1–5]. Late onset neonatal sepsis (LONS) occurs 
after three days of life and may be caused by pathogens 
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acquired at delivery or during the course of hospital care 
[6]. Although in most cases LONS onset is often incon-
spicuous, the clinical course may be alarmingly fulminant 
leading to septic shock and death within hours of onset 
[7, 8]. Infected neonates must therefore be promptly 
identified, and additionally, sepsis severity should ideally 
be assessed at moment of onset to intensify and adapt 
monitoring and therapy. Several chemical biomarkers 
are used to diagnose and monitor disease progression 
in patients suspected of sepsis. Three commonly used 
biomarkers are: C-reactive protein (CRP), procalcitonin 
(PCT) and interleukin-6 (IL-6) [9]. CRP, the most fre-
quently used laboratory test for the diagnosis of neona-
tal sepsis, is extensively studied in routine practice and 
available as point of care test [10]. However, CRP level 
at onset is proven not predictive of LONS diagnosis [11]. 
PCT is an acute phase reactant and the PCT response is 
more rapid than the elevation of CRP [12, 13]. IL-6 is a 
pro-inflammatory cytokine and increases rapidly before 
PCT or CRP increases in neonatal septic patients [12].
For individual patient management, it is unclear which 
patients are most likely to have a severe sepsis or which 
are least likely to survive at moment of sepsis suspicion 
and thus would benefit from more intensive monitoring 
and from alternative treatment approaches. Risk assess-
ment would greatly aid decision-making in individual 
patients. Recently, a new sepsis severity score (e.g., organ 
dysfunction) was adapted from adults for use in preterm 
neonates with LONS. This score, the neonatal Sequential 
Organ Failure Assessment (nSOFA) score, consists of res-
piratory, cardiovascular and hematological criteria [14]. 
A high score (> 4 points out of a maximum of 15) 12  h 
after onset is associated with mortality [14].
Little is known about the predictive value of inflamma-
tory biomarker responses in preterm infants suspected 
of LONS. Nevertheless, CRP seems the most commonly 
used and widely implemented biomarker. Furthermore, 
few studies have purposefully attempted to evaluate bio-
markers that could objectively reflect the risk of mortality 
and sepsis severity of neonatal sepsis in neonates sus-
pected of LONS [15, 16]. The aim of the current study is 
to investigate the association of inflammatory biomark-
ers at moment of suspicion of LONS with subsequent 
risk of mortality and sepsis severity in preterm infants 
(< 32 weeks of gestation at birth).
Material and methods
Study design and population
The study was conducted at the Erasmus MC University 
Medical Center–Sophia Children’s Hospital Rotterdam, a 
level IV neonatal intensive care unit (NICU). Patient data 
from January 2018 until October 2019 were reviewed 
for all neonates with signs and symptoms suggestive of 
systemic infection, in whom blood was taken for blood 
culture and for inflammatory biomarkers determinations.
Ethical approval
The study was approved by the local ethical board of the 
Erasmus MC, University Medical Center. No explicit 
informed consent was obtained, the ethical board 
resumed responsibility. As part of standard care patients 
are asked for consent to use data for future medical 
research when admitted to our NICU.
Definition of sepsis
The Department of Microbiology provided all results of 
blood cultures, including timing of collection and identi-
fied micro-organisms. We excluded all control blood cul-
tures. One patient could provide multiple cases of sepsis. 
Sepsis diagnosis was established by the criteria defined 
by the NICHD Neonatal Research Network [17]. LONS 
was defined as a positive blood culture obtained after 
72 h of life and intent to treat with antibiotics for 5 days 
or more. An episode of culture proven sepsis was defined 
as a positive blood culture due to an identified bacterial 
organism (including coagulase-negative staphylococci), 
treated with antibiotics for 5 days or more or treated for 
a shorter duration if death occurred during treatment 
[17]. Culture negative sepsis was defined as (1) C-reactive 
protein level greater than 10 mg/L within two days after 
blood culture, (2) antibiotic treatment longer than 5 days 
(or intention to treat longer) and (3) clinical signs of sep-
sis assessed by treating physician.
Patient characteristics
The following patient characteristics were obtained from 
clinical charts: sex, gestational age, birthweight and post-
natal age at suspicion. Data of the mother were collected 
from the Dutch Neonatology Register (LNR): age, hyper-
tension, gestational diabetes, prolonged preterm rupture 
of membranes (pPROM), maternal fever, antenatal corti-
costeroid therapy and multiple birth.
Biomarkers
The biomarkers included in the analysis were serum IL-6, 
CRP and PCT. Biomarker levels were measured by the 
department of Clinical Chemistry and were retrospec-
tively queried from the laboratory information system. 
Blood samples were taken at the time of the initial sepsis 
suspicion (0 h).
CRP levels were measured using a turbidimetric 
method (C502, Cobas 8000 system, Roche Diagnostics, 
Rotkreuz, Switzerland). PCT and IL-6 were both meas-
ured using Electro-Chemi Luminescent Immuno Assay 
(ECLIA) tests (E801, Cobas 8000 system, Roche Diagnos-
tics, Rotkreuz, Switzerland).
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Plasma levels of CRP, PCT and IL-6 were routinely 
determined as part of a diagnostic local workup proto-
col whenever sepsis was suspected in infants. No other 
cytokines were included in this protocol. At our center, 
we use heart rate observation (HeRO) monitoring in pre-
term infants as an early warning score for LONS [18]. 
According to local protocol, clinicians can consider to 
determine chemical biomarkers when the HeRO score is 
increased. Blood cultures are drawn and antibiotic treat-
ment is started when the neonate shows evident clini-
cal signs of sepsis or when CRP, PCT or IL-6 levels are 
increased.
Outcome measurements
The primary outcome was mortality within 7 days of sus-
picion of sepsis. The secondary outcomes were measures 
of sepsis severity; nSOFA score [14], need of inotropic 
therapy, need of mechanical ventilation and thrombocy-
topenia within 3  days of suspicion. The nSOFA param-
eters were obtained from clinical charts to calculate the 
nSOFA scores at time point, t = 12  h. A high nSOFA 
score was defined as more than 4 points out of a maxi-
mum of 15 at 12  h after onset. Inotropic support was 
defined as the start of inotropes after sepsis suspicion. 
Need for mechanical ventilation was defined as the need 
for intubation within 72 h after suspicion. If the patient 
was already intubated at moment of suspicion, this sep-
sis episode was excluded for analysis with this specific 
secondary outcome. Thrombocytopenia was defined as a 
platelet count < 50 × 109/L.
Statistical analysis
Statistical analysis was performed using R (R Core Team 
(2017), Vienna, Austria).
Categorical variables were described using absolute 
and relative frequencies. Continuous variables were 
described using medians and range (min–max) because 
of non-normal distributions.
A receiver operating characteristic (ROC) analysis was 
used to investigate the predictive value of each biomarker 
for 7-day mortality; a high nSOFA score at 12 h (nSOFA 
score > 4 [14]); inotropic support; intubation; and throm-
bocytopenia within 3 days. The exploratory optimal cut-
off point for each biomarker was calculated using the R 
package ‘OptimalCutpoints.’ The Youden index was used 
to calculate the optimal cutoff points [19]. The Youden 
index calculates the cutoff point that optimizes the bio-
marker’s differentiating ability when equal weight is given 
to sensitivity and specificity. The cutoff point for predict-
ing intubation was calculated by maximizing the specific-
ity, to identify high risk patients to increase awareness in 
clinical practice. The effect of each biomarker on 7-day 
mortality was estimated using Cox regression models. 
We performed two sensitivity analyses; one addition-
ally adjusting for previous sepsis episodes and the other 
for the type of infection. Due to the limited number of 
events, we were able to adjust for three possible con-
founders. All analyses were adjusted for sex, gestational 
age and birthweight. We investigated the 7-day survival 
using the Kaplan–Meier method. There is a lack of age 
specific reference values for these biomarkers. Based on 
the optimal cutoff analysis described before, the Kaplan–
Meier method was used to estimate survival across 
groups with different levels of biomarkers at onset. The 
log-rank test was used to compare survival across groups 
with different levels of biomarkers.
The statistical analysis was performed on raw or loga-
rithmically transformed data where appropriate. For all 




In the study period, a total of 480 episodes of suspected 
LONS in 208 prematurely born patients (< 32  weeks 
of gestation at birth) occurred. Of these episodes, 143 
(29.8%) were classified as sepsis. Gram-positive sep-
sis was most common (63 cases (13.1%), predominantly 
Coagulase-negative Staphylococci (CoNS) (48%) and 
Staphylococcus aureus (16%)). Gram-negative sepsis 
occurred less frequently (24 cases (5.0%), the most com-
monly found gram-negative organism was Escherichia 
coli (19%) (see Table  1)). Baseline maternal and patient 
characteristics are summarized in Table  1. The median 
gestational age of the neonates was 26 weeks and 3 days 
(range: 24 + 0–31 + 6), and the median birthweight was 
850 (range: 445–2100) grams.
Figure 1 shows the plasma concentrations of IL-6, PCT 
and CRP at the time of sepsis suspicion (0 h). Biomarker 
levels in patients with sepsis differed significantly com-
pared with patients without sepsis (p < 0.001 for all bio-
markers). Excluding culture negative sepsis episodes did 
not affect the differences in biomarker levels when com-
paring patients with sepsis and without sepsis (see Addi-
tional file 1).
Mortality
In the entire study population, a total of 24 sepsis epi-
sodes in 22 patients resulted in death within 7  days 
(5.0%). Log IL-6 levels were associated with 7-day mortal-
ity (adjusted hazard ratio (aHR): 2.28; 95% CI (1.64–3.16; 
p < 0.001), in a model corrected for birth weight, gesta-
tional age and sex. Similarly, log PCT levels were associ-
ated with 7-day mortality (aHR: 2.91; 95% CI (1.70–5.00; 
p < 0.001). Contrarily, log CRP levels were not associated 
with 7-day mortality (aHR ratio: 1.16; 95% CI (0.68–2.00; 
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p = 0.56). Sensitivity analyses showed that these associa-
tions are independent of previous sepsis episodes and the 
type of infection (see Additional files 2 and 3).
The area under the curve for predicting mortality was 
0.64 (95% CI 0.48–0.79) for IL-6, and an exploratory cut-
off point could be established at 580 pg/mL, with a sensi-
tivity of 50.0% and a specificity of 89.9% (see Fig. 2). The 
area under the curve (AUC) for PCT was 0.74 (95% CI 
0.64–0.84), and an exploratory PCT cutoff point could be 
established at 0.94 ng/mL. At this value, PCT reached a 
sensitivity of 77.3% and a specificity of 64.9%. The AUC 
for CRP was 0.52 (95% CI 0.40–0.65), and an exploratory 
CRP cutoff point could be established at 7.9 mg/L, with a 
sensitivity of 47.8% and a specificity of 65.8% (see Fig. 2). 
The Kaplan–Meier survival curves of the 7-day survival 
significantly differed across the two IL-6 categories with 
cutoff 580 pg/mL and the two PCT categories with cut-
off 0.75 ng/mL, both p < 0.001 (see Fig. 3 panel A and B). 
Survival did not differ across the CRP categories with 
cutoff 8 mg/L at onset of sepsis, p = 0.33 (see Fig. 3 panel 
C).
nSOFA score
ROC curves and AUCs for IL-6, PCT and CRP were cal-
culated with respect to predicting a nSOFA score above 4 
at 12 h after onset. IL-6, PCT and CRP showed an AUC 
value of 0.668 (95% CI, 0.55–0.79), 0.776 (95% CI, 0.69–
0.87) and 0.658 (95% CI, 0.55–0.76), respectively (see 
Fig. 4).
An exploratory IL-6 cutoff point could be established 
at 548 pg/mL. At this value, IL-6 reached a sensitivity of 
48.3% and a specificity of 90.5%. An exploratory PCT cut-
off point could be established at 1.06 ng/mL, with a sen-
sitivity of 80.0% and a specificity of 70.2%. An exploratory 
CRP cutoff point could be established at 6.4 mg/L, with a 
sensitivity of 61.3% and a specificity of 65.3%.
Table 1 Patient and mother baseline characteristics
a Prolonged premature rupture of membranes
b Number of doses of antenatal betamethasone therapy
c Coagulase negative staphylococci
Values are medians (min–max range) or percentages
Variable Total episodes (n = 480)
Age of the mother (years) 30 (18–43)
Hypertension Pregnancy Disorder (PIH/PE) 107 (22.3%)
Gestational diabetes 33 (6.9%)
pPROMa 85 (17.7%)
Maternal Fever 22 (4.6%)
Antenatal corticosteroid  therapyb
 None 64 (13.3%)
 1 dose of betamethasone 113 (23.5%)
 2 doses of betamethasone 295 (61.5%)
Singleton 386 (80.4%)
Sex (male) 249 (51.9%)
Gestational Age (weeks) 26 + 3 (24 + 0 – 31 + 6)
Post menstrual age (weeks) 29 + 1 (24 + 4 – 51 + 3)
Birthweight (grams) 850 (445–2100)
Age at Evaluation (days) 13 (4–165)
IL-6 level at onset (pg/mL) 45 (2–1396700)
PCT level at onset (ng/mL) 0.67 (0.02 – 100)
CRP level at onset (mg/L) 3.45 (0.3 – 309.0)
Mortality 24 (5%)
Type of infection
 No infection 337 (70.2%)
 Culture negative 56 (11.7%)
 Culture proven sepsis 87 (18.1%)
 Gram positive (% of total proven sepsis) 63 (72%)
    CoNSc 42 (48%)
    S. aureus 14 (16%)
    Others 7 (8%)
 Gram negative (% of total proven sepsis) 24 (28%)
    E.Coli 17 (19%)
    Klebsiella 4 (5%)
    Others 3 (4%)
nSOFA score
nSOFA score at t = 12 h 0 (0–11)
Number of suspected episode
 1 suspected episode 84
 2 suspected episode 46
  > 2 suspected episodes 78
Fig. 1 Biomarker levels at moment of suspicion. Log transformed 
plasma concentrations of IL-6 (pg/mL), PCT (ng/mL) and CRP (mg/L) 
at the time of sepsis evaluation across patients with sepsis (both 
culture negative and culture positive sepsis) and without sepsis. Data 
are presented as Log(10) transformed data because of the wide range 
in biomarker levels and comparability. * P < 0.001 
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Inotropic and respiratory support and thrombocytopenia
Inotropic support
Log IL-6, log PCT and log CRP levels were all signifi-
cantly correlated with the need for inotropic support 
with an aHR of 2.41 (95% CI 1.93–3.00; p < 0.001); 4.24 
(95% CI 3.02–5.96; p < 0.001) and 2.0 (95% CI 1.41–2.90; 
p < 0.001), respectively).
ROC curves and AUC values for IL-6, PCT and CRP 
were calculated with respect to predicting inotropic sup-
port need, intubation and thrombocytopenia within 
3 days of suspicion. AUC values with their respective 95% 
confidence intervals, exploratory cutoff points with sen-
sitivity and specificity are depicted in Table 2 for each of 
the biomarkers. In total, 79 patients were excluded from 
the respiratory support analysis, due to being already 
ventilated at moment of sepsis suspicion.
Discussion
LONS is a relevant issue in every NICU, and an early 
assessment of sepsis severity has the potential to improve 
quality of care. In this large retrospective study, we 
assessed the association between IL-6, PCT and CRP 
at onset and subsequent sepsis severity and mortality. 
Up until now, little has been known about the prognos-
tic value of IL-6 and PCT for disease severity in preterm 
neonates suspected of LONS. Our results show that 
serum IL-6 and PCT, but not CRP, are associated with 
7-day mortality in preterm infants suspected of LONS. 
IL-6, PCT and CRP at onset of sepsis were associated 
with various clinical measures of sepsis severity, such as 
need for inotropic support and mechanical ventilation, 
with IL-6 and PCT showing the strongest associations, 
with a higher discriminative value compared to CRP. To 
our knowledge, no other study investigated the associa-
tion of these biomarkers with measures of sepsis sever-
ity. Determining these biomarkers in suspected LONS 
can help clinicians to identify neonates with possible 
imminent severe sepsis at moment of suspicion. The 
investigated biomarkers can be determined rapidly, usu-
ally within the matter of an hour and a half, and while 
the biomarker levels were related to the type of infec-
tion (e.g., gram-negative infections) they independently 
predicted the subsequent mortality risk. This risk assess-
ment increases awareness and may lead to personalized 
monitoring. For example, peripheral arterial blood pres-
sure measurement could be considered when high risk 
patients are identified, to monitor possible occurring 
of hypotension closely. Furthermore, they could enable 
personalized treatment, such as starting pentoxifylline 
in high risk patients [20]. Also, these biomarkers could 
provide a key for selecting patients at the highest risk for 
severe sepsis, in future clinical studies.
Fig. 2 ROC curves for IL6 (a), PCT (b) and CRP (c) with respect to predicting 7-day mortality
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CRP is the most commonly available test in hospitals 
for neonatal sepsis [10, 11, 21, 22]. It is both used for 
diagnosing sepsis and monitoring disease progression. 
However, a recent meta-analyses by Brown and col-
leagues in 2255 infants showed that CRP is insensitive 
and nonspecific for LONS diagnosis [11]. Based on the 
kinetics of CRP, it is not preferred as an early prognos-
tic and diagnostic marker; however, it has been shown 
that serial measurements of CRP could reliably rule-out 
infection 24 h after suspicion [23]. In the present study, 
we confirmed that CRP at onset of sepsis yields lim-
ited information on subsequent sepsis severity and risk 
of mortality. This is also in line with one small study by 
Romagnoli et al., which did not find a significant correla-
tion of CRP levels at onset of sepsis and mortality in 39 
preterm infants suspected of sepsis [24].
Little has previously been known about the prognos-
tic value of IL-6 in neonates suspected of sepsis. We 
show that IL-6 can offer valuable information about the 
subsequent sepsis severity and risk of mortality among 
premature neonates suspected of LONS. Two other 
smaller studies showed inconsistent results of IL-6 and 
risk of mortality. Boskabandi et al. showed in 84 preterm 
and term patients that IL-6 might be valuable in predict-
ing sepsis mortality [25], while Romagnoli et al. did not 
find a statistical significant difference in IL-6 levels in 39 
septic preterm infants in survivors and non-survivors 
[24]. Studies in older pediatric patients and adults are 
in line with our findings; in these patients with sepsis, 
higher levels of IL-6 at the onset of sepsis are associated 
with a poorer outcome [26–28].
Serum PCT is a promising biomarker of increasing 
interest for detecting serious bacterial infections [29] and 
can be used for guiding duration of antibiotic therapy 
in early onset sepsis [30]. Our results suggest that PCT 
might also be a useful marker in predicting disease sever-
ity in LONS. However, caution is required when inter-
preting PCT levels [31] in an individual patient. Hahn 
Fig. 3 Kaplan–Meier survival curves. Primary end point of 7-day mortality according to IL-6 (a), PCT (b) and CRP (c) category at moment of sepsis 
suspicion
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Fig. 4 ROC curves for IL6 (a), PCT (b) and CRP (c) with respect to predicting a high nSOFA score (> 4) at t = 12 h after suspicion of sepsis
Table 2 Prediction of inotropic and respiratory support and thrombocytopenia
Data represent AUC values with their respective 95% confidence intervals, exploratory cutoff points with sensitivity and specificity for each biomarker
Total population (n = 480) Interleukin-6 Procalcitonin C-reactive protein
Inotropic support N = 67 cases (14%)
AUC 0.71 0.79 0.65
95% CI 0.63–0.80 0.63–0.80 0.56–0.73
Exploratory cutoff 118 pg/mL 1.03 ng/mL 6.3 mg/L
Sensitivity 63.1% 79.6% 58.9%
Specificity 77.8% 71.1% 65.7%
Thrombocytopenia N = 79 cases (16.5%)
AUC 0.77 0.83 0.79
95% CI 0.67–0.88 0.72–0.93 0.69–0.89
Exploratory cutoff 391 pg/mL 1.89 ng/mL 11.0 mg/L
Sensitivity 60.0% 79.2% 80.0%
Specificity 88.1% 82.3% 72.6%
Total population (n = 401)
Respiratory support N = 68 cases (17%)
AUC 0.67 0.72 0.59
95% CI 0.60–0.74 0.65–0.80 0.51–0.67
Exploratory cutoff 201 pg/mL 1.6 ng/mL 27 mg/L
Sensitivity 39.7% 45.3% 23.9%
Specificity 85.6% 85.8% 86.9%
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et  al. found that gestational age at birth and postnatal 
age had a significant effect on normal PCT levels, with 
more immature patients within early postnatal life having 
a wide range of PCT levels in a non-septic situation [31]. 
To the best of our knowledge, no other studies evaluated 
the value of PCT in predicting mortality or sepsis sever-
ity in LONS. Our study highlights a possible role of PCT 
in guiding clinical management.
Recently, Wynn et  al. developed the nSOFA score, a 
sepsis severity score consisting of respiratory, cardiovas-
cular and hematological criteria  [14] and showed that a 
high score 12 h (> 4 out of 15) after onset of sepsis was 
associated with mortality. Biomarker levels of IL-6, PCT 
and CRP were associated with this composite outcome of 
sepsis severity, in which PCT had the highest diagnostic 
accuracy. Also, the biomarker levels were associated with 
each component of the nSOFA score (need for inotropic/
mechanical support and thrombocytopenia). This high-
lights that these biomarkers at the moment of suspicion 
could provide information on the subsequent clinical 
course of the sepsis in a specific individual. To our knowl-
edge, no other studies investigated the association of 
these biomarkers with measures of sepsis severity. These 
findings could help clinicians differentiate patients with 
possible severe sepsis at moment of suspicion, increase 
awareness for imminent clinical deterioration and also 
enable to personalize sepsis therapy.
There are some remarks for interpreting the study 
results. First, in our center we use heart rate observation 
(HeRO) monitoring [32] as an early warning system of 
sepsis. Based on changes in heart rate characteristics, we 
consider determining inflammatory biomarkers, possi-
bly early in sepsis, when clinical signs are absent or non-
specific. In centers without such monitoring, biomarkers 
could be determined later in the course of sepsis, which 
could affect the associations we found. For instance, after 
a rapid increase of IL-6 the levels also decrease rapidly 
and provide less information on future clinical course 
compared to determining IL-6 early in sepsis. This may 
limit generalizability of the results of our study. Sec-
ond, if a patient had multiple suspected sepsis episodes 
we included all unique episodes independent of previ-
ous proven, culture negative or non-septic episodes. We 
hypothesized that the association between biomarker 
levels and subsequent mortality risk or sepsis severity is 
not modified by previous sepsis periods which a patient 
survived. Sensitivity analyses adjusting for previous sep-
sis episodes did not change the results materially. Fur-
thermore, in daily clinical practice we would also not 
interpret a biomarker taking into account previous epi-
sodes. Our study also has limitations. We performed a 
retrospective cohort study including all patients with a 
gestational age < 32  weeks admitted to our hospital. We 
obtained many variables and outcome data from clinical 
charts, which may lead to misclassification due to mis-
takes in data entry. If misclassification would occur, we 
would expect this random misclassification decreasing 
precision of the effect estimates. We tried to limit missing 
data and misclassification by using automated registries 
for biomarker levels and blood cultures from the depart-
ments of clinical chemistry and microbiology respec-
tively, and double data entry from the clinical charts to 
reduce data entry errors. Furthermore, despite being the 
largest cohort study investigating biomarkers levels in 
preterm neonates with suspected LONS, the number of 
events in our study is relatively small, limiting the ability 
to test model performance for calculated cutoff values in 
a validation sample.
Future research should focus on validating our findings 
in independent and larger populations. Furthermore, in 
this study we looked at short-term outcome measures; 
future research could focus on the relationship of these 
biomarkers with long-term (neurodevelopmental) out-
comes measures.
Conclusion
In conclusion, our findings demonstrate that IL-6 and 
PCT offer valuable information about disease sever-
ity in subsequent clinical course and mortality risk in 
suspected preterm LONS. Both IL-6 and PCT are more 
informative than CRP and could guide personalized 
intensive monitoring and increase awareness for immi-
nent clinical deterioration and timely intervention.
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plasma concentrations of IL-6 (pg/mL), PCT (ng/mL) and CRP (mg/L).
Additional file 3. Table: Estimates of hazard ratios of each biomarker for 
7-day mortality with and without adjusting for type of infection. Descrip-
tion of data: 1Type of infection defined in 4 categories: no – culture 
negative – gram-positive – gram-negative sepsis. Effect estimates reflect 
the hazard ratio with their 95% confidence intervals. *p< 0.05 ** p<0.001. 
Biomarker levels are Log(10) transformed plasma concentrations of IL-6 
(pg/mL), PCT (ng/mL) and CRP (mg/L).
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